A fungating mass is a tumor that has broken through the skin, creating an open wound that grows outward and destroys the tissue around it. The name comes from the Latin word “fungus” because the lesion can resemble a mushroom or cauliflower as it proliferates on the skin’s surface. These wounds are among the most distressing complications of advanced cancer, affecting roughly five to ten percent of cancer patients, and they present a set of management challenges that go well beyond what most people associate with wound care.
How a Fungating Mass Forms
A fungating mass develops when cancer cells invade the skin and break down the surrounding tissue, including the blood vessels that normally support healthy skin. This can happen in three ways: a primary skin tumor grows large enough to erode through the surface, a tumor from deeper in the body pushes outward into the skin, or cancer that has spread from elsewhere in the body seeds itself in or just beneath the skin as a metastasis. In its earliest stages, the affected area may simply look inflamed, with redness, warmth, firmness, and tenderness before the skin eventually breaks down into an open wound.1PubMed Central. Management of malignant cutaneous wounds in oncologic patients
Once the skin barrier is breached, the wound tends to progress because the tumor continues to grow while also disrupting the normal healing process. The blood supply feeding the wound is often abnormal and fragile, which contributes to bleeding and makes it harder for the body to fight infection or close the wound on its own. The result is a lesion that may look like an open crater, a raised nodule, or a spreading fungus-like growth, depending on how the tumor is growing.
Which Cancers Cause Them and How Common They Are
Fungating wounds can arise from virtually any type of cancer, but breast cancer is the most common culprit by a wide margin. After the breast, the most frequent locations are the neck, chest wall, extremities, genitals, and head. Most of these wounds appear during the last six to twelve months of a patient’s life, though they can persist for years in people living with advanced disease.2PubMed Central. Management of malignant cutaneous wounds in oncologic patients In one randomized study of thirty cancer patients with malodorous fungating wounds, twenty-four of the thirty had breast-related lesions, with the remainder spread across the neck, groin, spine, and anus.3Proceedings of Singapore Healthcare. Comparing the Effectiveness of Green Tea versus Topical Metronidazole Powder in Malodorous Control of Fungating Malignant Wounds in a Controlled Randomised Study
The five-to-ten-percent prevalence figure can be misleading because it spans all cancer types and stages. In certain populations, such as patients with locally advanced breast cancer who have delayed seeking treatment, the rate is much higher. Fear, financial barriers, and a tendency to downplay symptoms all play a role in delayed diagnosis. Research in resource-limited settings has documented that patients and families sometimes normalize early symptoms as aging or fatigue, or avoid doctors out of fear of a cancer diagnosis, allowing tumors to progress to the point where they break through the skin.4PubMed Central. Being sick to a cancer patient: pathways of delay in help seeking and diagnosis of cancer in India
The Symptoms That Define Them
What makes fungating masses especially burdensome is not just the wound itself but the cluster of symptoms that accompany it. The main issues are odor, heavy drainage (exudate), pain, and a risk of bleeding. Management usually aims to slow the disease and improve quality of life by controlling these physical symptoms through appropriate dressings and topical agents.5PubMed Central. Topical agents and dressings for fungating wounds
Pain in a fungating wound is not one-dimensional. Patients report deep aching pain from the tumor pressing on underlying structures, nerve-related pain from cancer infiltrating nearby nerves, and surface-level pain triggered by dressing changes or wound cleaning. Systemic pain medication forms the backbone of management, and clinicians typically recommend giving a fast-acting painkiller before starting any dressing change so the patient is not caught off guard.6Seminars in Oncology Nursing. Management of Malignant Fungating Wounds in Advanced Cancer
Bleeding is another constant concern. Because the tumor creates abnormal, fragile blood vessels, even gentle contact during wound care can cause bleeding. This can range from minor oozing to sudden, frightening hemorrhages, particularly if the wound erodes into a larger vessel. For patients at home, caregivers often live with a low-level anxiety about the possibility of a bleed that they are not equipped to handle.
Why the Smell Is So Difficult
Of all the symptoms, odor is often cited as the single most distressing one for both patients and the people around them. The smell does not come from the tumor itself in a direct sense. It comes from bacteria that colonize the moist, dead tissue inside the wound. A mix of anaerobic microbes (bacteria that thrive without oxygen) moves into the necrotic areas of the wound and produces foul-smelling fatty acids as metabolic byproducts. Eliminating these anaerobes tracks closely with improvements in odor.7PubMed Central. Successful management of malodor from fungating tumors using crushed metronidazole tablets The interaction between both aerobic and anaerobic bacteria colonizing and infecting the wound drives the characteristic smell.8Journal of Hospice & Palliative Nursing. Odor Management in Fungating Wounds With Metronidazole
The odor is not a minor aesthetic complaint. It can be strong enough to fill a room and detectable even through multiple layers of dressing. Patients often withdraw socially because they feel humiliated, and caregivers can struggle with nausea while providing wound care. The combination of a visible wound and a pervasive odor makes it nearly impossible for many patients to maintain their previous social lives.
Controlling Odor and Exudate
The front-line approach to odor control is topical metronidazole, an antibiotic with strong activity against anaerobic bacteria. Applied directly to the wound as a gel, cream, or crushed powder, metronidazole attacks the bacteria responsible for the smell. In a multicenter trial, topical metronidazole gel achieved odor control (defined as no or minimal odor) in about ninety-five percent of patients by day fourteen.9PubMed Central. Safe and effective deodorization of malodorous fungating tumors using topical metronidazole 0.75 % gel (GK567): a multicenter, open-label, phase III study (RDT.07.SRE.27013)
Interestingly, metronidazole is not the only option with evidence behind it. A randomized study compared green tea applied to the wound against topical metronidazole powder. Both groups showed improvement in odor by day seven, and the researchers found no statistically significant difference between the two treatments.10Proceedings of Singapore Healthcare. Comparing the Effectiveness of Green Tea versus Topical Metronidazole Powder in Malodorous Control of Fungating Malignant Wounds in a Controlled Randomised Study The study was small, with only thirty patients, so green tea is not a proven replacement, but it suggests there may be alternatives when metronidazole is unavailable or poorly tolerated.
Medical-grade honey has also attracted attention for its deodorizing and wound-cleansing properties. Clinicians have used honey-based products in fungating wounds primarily for rapid odor reduction and to help balance wound moisture levels. Combining a honey wound gel, non-adherent gauze, and foam dressing is one approach reported to control exudate while improving comfort.11PubMed Central. Medical-Grade Honey Is a Versatile Wound Care Product for the Elderly
Beyond topical antimicrobials, wound cleansing and debridement (removing dead tissue) are standard parts of infection and odor control.12Seminars in Oncology Nursing. Management of Malignant Fungating Wounds in Advanced Cancer Absorbent dressings help manage exudate so that the wound surface stays moist enough to avoid painful adherence but not so wet that it breeds more bacteria. Charcoal-containing dressings are sometimes layered on top to absorb odor before it reaches the air. The dressing regimen typically needs to be individualized and adjusted frequently as the wound changes.
Radiation Therapy and Tumor Regression
While local wound care manages symptoms day to day, radiation therapy can address the underlying cause by shrinking the tumor itself. Palliative radiation does not aim to cure the cancer but to reduce the mass enough to relieve symptoms. Case reports document dramatic responses: one patient with a fungating breast mass showed an immediate and lasting regression after radiation, with a significantly improved quality of life.13PubMed Central. Dramatic Regression of a Fungating Breast Lesion Treated with Radiation Therapy
Larger analyses support the idea that radiation is not just an anecdotal success story. Data from a tertiary cancer center found that radiotherapy for malignant fungating wounds produced very high rates of local tumor regression, which in turn reduced the cascade of quality-of-life problems these wounds cause.14PubMed Central. Radiotherapy in the treatment of malignant fungating wounds: clinical practice, response rates, and outcome from a tertiary cancer center A systematic review of cohort studies also found that the proportion of patients receiving radiotherapy and targeted therapy for fungating breast cancers has increased significantly over recent years, suggesting that oncologists are increasingly turning to these approaches rather than relying solely on wound care.15PubMed Central. Therapeutic strategies for fungating and ulcerating breast cancers: A systematic review and narrative synthesis
Electrochemotherapy and Targeted Drug Therapy
For patients whose wounds are not easily managed with radiation or surgery, electrochemotherapy has emerged as a newer option. The technique uses brief electrical pulses applied to the tumor surface to temporarily open the cell membranes, allowing a chemotherapy drug (typically bleomycin or cisplatin) to flood the cancer cells at much higher concentrations than it could reach on its own. A systematic review and meta-analysis concluded that electrochemotherapy is an effective, repeatable, and minimally invasive intervention that can reduce the symptom burden associated with cutaneous disease in palliative patients.16PubMed. Electrochemotherapy for the palliative management of cutaneous metastases: A systematic review and meta-analysis From a palliative wound-care perspective, it offers a standardized way to contain and slow the advancement of cutaneous and subcutaneous metastases regardless of the cancer’s tissue of origin.17Current Opinion in Supportive and Palliative Care. Malignant wound management in advanced illness: new insights
Targeted drug therapies are another avenue when the cancer’s molecular profile makes it eligible. In one striking case, a patient with a melanoma that had formed a large fungating soft tissue mass was found to carry a specific genetic mutation (BRAF). Within weeks of starting targeted therapy with two drugs aimed at that mutation, the mass showed an impressive local response, and the patient was spared a palliative amputation.18Operative Techniques in Orthopaedics. BRAF-Mutant Metastatic Melanoma Presenting as a Fungating Soft Tissue Mass Suspicious for Sarcoma This kind of outcome depends entirely on the tumor having a drug-targetable mutation, so it is not available to everyone, but it illustrates how rapidly fungating wounds can improve when the right systemic treatment is matched to the right cancer.
Assessing and Tracking These Wounds
One underappreciated challenge with fungating masses is that clinicians have lacked standardized tools to assess them. Unlike pressure ulcers or diabetic foot wounds, which have well-validated scoring systems, malignant fungating wounds have only recently been the subject of dedicated assessment research. A scoping review identified twenty-two instruments used across forty studies, but only four were specifically designed for these wounds, all based on a framework called the Malignant Wound Assessment Tool. Of those, only two versions were validated in English, and neither had undergone full psychometric testing. The tools also lacked comprehensive coverage of key symptoms like odor and emotional impact.19PubMed Central. Malignant fungating wounds assessment in palliative care: a scoping review
The Malignant Wound Assessment Tool itself was developed in two versions: a brief clinical version for bedside use and a more detailed research version. Both cover clinical wound features, physical effects, and the emotional and social impacts of the wound. They went through expert review for content and construct validity, and the developers consider them ready for clinical application, but the broader wound-care community has been slow to adopt them.20PubMed. The malignant wound assessment tool: a validation study using a Delphi approach A separate effort to validate the research version through patient interviews is ongoing, underscoring how much work remains before clinicians have a truly reliable way to measure what patients with these wounds are experiencing.21PubMed Central. Validation of the Malignant Wound Assessment Tool – Research (MWAT-R) using cognitive interviewing
This gap matters in practice. Without a standardized way to score wound severity and track changes over time, it is harder to determine whether a treatment is working, to compare outcomes across studies, or to ensure that the full range of a patient’s suffering is being captured in their medical record.
The Toll on Patients and Caregivers
The physical symptoms are only part of the picture. Qualitative research on what patients with malignant fungating wounds actually experience has identified five major themes: physiological limitations, psychological changes, social challenges, disease management needs, and the need for support and care.22PubMed. The Experiences and Needs of Patients With Malignant Fungating Wounds: A Meta-Synthesis of Qualitative Studies The wound becomes a constant, visible reminder of the cancer, and many patients describe shame, disgust, and a feeling that their body is decaying while they are still alive. Social withdrawal is common, driven by both the odor and the appearance of the wound.
Caregivers carry an enormous burden as well. Research on family caregivers found that the visibility of the cancer was one of the most shocking aspects of the experience, altering the relationship between patient and carer. The wound gradually became the center of both their lives, consuming large amounts of time and energy as they tried to control symptoms like odor and copious discharge. Many caregivers managed the wound entirely on their own, without help or advice from healthcare practitioners, and described feeling isolated and overwhelmed.23PubMed. Caring for a loved one with a malignant fungating wound A broader review echoed these findings, noting that both families and nurses encounter significant obstacles and burdens when caring for patients with these wounds.24Journal of Wound, Ostomy and Continence Nursing. Caring for Patients With Malignant Fungating Wounds: A Scoping Literature Review
Part of what makes the caregiver experience so difficult is the lack of guidance. Many wound-care resources are geared toward wounds that are expected to heal. A fungating wound, by contrast, is not going to close. The goals are different: comfort, odor control, preventing infection, and maintaining dignity. Caregivers who are not told this explicitly may interpret the wound’s worsening as a failure, adding guilt to an already devastating situation.
When a Fungating Mass Is Not From Cancer
Though fungating masses are overwhelmingly associated with malignancy, the term can occasionally appear in clinical descriptions of non-cancerous growths that break through the skin in a similar fashion. Large benign tumors, severe infections, or inflammatory conditions can very rarely produce wounds that look fungating on the surface. The distinction matters because the management strategy depends entirely on whether an active malignancy is driving the wound. Any new skin lesion that is growing, breaking down, or failing to heal should be biopsied. Assuming a wound is benign because it does not hurt or because the patient has no known cancer history is a common and sometimes costly mistake. The biopsy is what separates a fungating malignant wound from other possibilities and determines the entire treatment pathway.
For patients already known to have cancer, a new skin nodule or a wound that refuses to heal at a surgical site should prompt the same suspicion. Skin metastases can appear months or years after the original cancer was treated, and their initial presentation can be surprisingly subtle before they evolve into a full fungating mass.
Practical Realities of Living With One
Day-to-day life with a fungating wound revolves around dressing changes. Depending on how much the wound drains, dressings may need to be changed once or multiple times a day. Each change involves removing the old dressing (ideally after soaking it to avoid tearing tissue), cleaning the wound, applying any topical medications, and layering fresh absorbent and odor-trapping materials. It is a time-consuming process, and when done at home, it typically falls to one family member who learns through trial and error.
Supplies are another practical concern. Absorbent dressings, non-adherent contact layers, antimicrobial gels, barrier creams, and charcoal dressings add up quickly. Insurance coverage varies, and patients in some healthcare systems find it difficult to get the specialty wound-care products that work best. Substituting cheaper alternatives can lead to dressings that stick, leak, or fail to contain odor, which directly impacts the patient’s willingness to leave the house or have visitors.
Sleep disruption is frequently underreported. The wound may leak through dressings overnight, requiring bedding changes. Pain can worsen at night when there are fewer distractions. And the psychological weight of the wound, its smell, its appearance, what it represents, keeps many patients awake long after the physical discomfort is managed. Healthcare teams that address only the wound itself without asking about sleep, mood, and social functioning are missing most of the picture.